MedTrace Logo

Biomarkers to Predict and Monitor Response to Infliximab

NCT04655729 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2022-04-13

No results posted yet for this study

Summary

The aim of the study is to generate novel minimally-invasive serum protein signatures and biomarkers in children and adolescents with Crohn's Disease (CD) that correlate with and can predict and monitor patients who will have a prolonged response to Infliximab so that personalized medicine can be applied to patients with CD.

Conditions

  • Crohn Disease

Interventions

DRUG

Infliximab

Blood collection

Sponsors & Collaborators

  • Crohn's and Colitis Foundation

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Eligibility

Min Age
3 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-18
Primary Completion
2022-11-30
Completion
2023-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04655729 on ClinicalTrials.gov